Status:
COMPLETED
The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Ischemic Heart Disease
Eligibility:
All Genders
20-80 years
Phase:
PHASE1
PHASE2
Brief Summary
The aim of this study was to evaluate the mobilization of non-haematopoietic mesenchymal and haematopoietic stem cells from the bone marrow with granulocyte colony stimulating factor (G-CSF) treatment...
Detailed Description
In recent clinical trials, vascular endothelial growth factor (VEGF) delivered as plasmid DNA percutaneously by a catheter-based, intramyocardial approach, have been demonstrated to be safe and to be ...
Eligibility Criteria
Inclusion
- Reversible ischemia at an adenosine stress single photon emission computerized tomography (SPECT)
- A coronary arteriography demonstrating at least one main coronary vessel from which new collaterals/vessels could be supplied
- Age above 18 years
- Canadian Cardiovascular Society angina classification (CCS) \> 3.
Exclusion
- Ejection fraction \<0.40
- Unstable angina pectoris
- Acute myocardial infarction within the last three months
- Diabetes mellitus with proliferative retinopathy
- Diagnosed or suspected cancer disease
- Chronic inflammatory disease
- Premenopausal women
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2005
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT00135850
Start Date
March 1 2003
End Date
February 1 2005
Last Update
August 5 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiac Catheterization Laboratory 2014, The Heart Centre, University Hospital, Rigshospitalet
Copenhagen Ø, Denmark, 2100